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Abstract
Background: Tuberculosis is one of the most prominent health problems in the world, causing
1.75 million deaths each year. Rapid clinical diagnosis is important in patients who have co-
morbidities such as Human Immunodeficiency Virus (HIV) infection. Direct microscopy has low
sensitivity and culture takes 3 to 6 weeks [1-3]. Therefore, new tools for TB diagnosis are
necessary, especially in health settings with a high prevalence of HIV/TB co-infection.
Methods: In a public reference TB/HIV hospital in Brazil, we compared the cost-effectiveness of
diagnostic strategies for diagnosis of pulmonary TB: Acid fast bacilli smear microscopy by Ziehl-
Neelsen staining (AFB smear) plus culture and AFB smear plus colorimetric test (PCR dot-blot).
From May 2003 to May 2004, sputum was collected consecutively from PTB suspects attending the
Parthenon Reference Hospital. Sputum samples were examined by AFB smear, culture, and PCR
dot-blot. The gold standard was a positive culture combined with the definition of clinical PTB. Cost
analysis included health services and patient costs.
Results:  The AFB smear plus PCR dot-blot require the lowest laboratory investment for
equipment (US$ 20,000). The total screening costs are 3.8 times for AFB smear plus culture versus
for AFB smear plus PCR dot blot costs (US$ 5,635,760 versus US$ 1,498, 660). Costs per correctly
diagnosed case were US$ 50,773 and US$ 13,749 for AFB smear plus culture and AFB smear plus
PCR dot-blot, respectively. AFB smear plus PCR dot-blot was more cost-effective than AFB smear
plus culture, when the cost of treating all correctly diagnosed cases was considered. The cost of
returning patients, which are not treated due to a negative result, to the health service, was higher
in AFB smear plus culture than for AFB smear plus PCR dot-blot, US$ 374,778,045 and US$
110,849,055, respectively.
Conclusion: AFB smear associated with PCR dot-blot associated has the potential to be a cost-
effective tool in the fight against PTB for patients attended in the TB/HIV reference hospital.
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Background
Tuberculosis is one of the most important health prob-
lems in the world, causing 1.75 million deaths each year,
in 2007. Rapid clinical diagnosis is more challenging in
patients who have co-morbidities, such as Human Immu-
nodeficiency Virus (HIV) infection. Direct microscopy has
low sensitivity and culture takes 3 to 6 weeks [1-3]. Diag-
nostic testing for tuberculosis has remained unchanged
for nearly a century, but newer technologies hold promise
for a revolution in tuberculosis diagnostics. Tests such as
the nucleic acid amplification assays allow more rapid
and accurate diagnosis of pulmonary and extrapulmonary
tuberculosis. The appropriate and affordable use of any of
these tests depends on the setting in which they are
employed [4,5]. New tools for TB diagnosis are necessary,
especially in health settings with a high prevalence of
HIV/TB co-infection.
In developing countries, in house polymerase chain reac-
tion (PCR) based on amplifying the IS6110 insertion ele-
ment can be used for the amplification of Mycobacterium
tuberculosis (MTB) DNA and offers the potential of a sen-
sitive, specific and rapid diagnostic for ruling out or con-
sidering pulmonary tuberculosis (PTB) [6-9].
The majority of previous studies have evaluated in house
and automated PCR and reported PCR sensitivities rang-
ing from 77% to 95% and PCR specificities of 95% in
smear-positive specimens, using culture as the gold stand-
ard and clinical criteria only to evaluate the discrepant
results. Moreover, the PCR tests were evaluated separately,
in contrast to clinical practice, where tests for diagnosis
are required in association [6,10,11]. Many prior studies
have observed that routine clinical use of PCR may be dif-
ficult due to its high cost, particularly if PCR is used by
itself, and emphasize the importance of clinical utility and
cost effectiveness analysis for these tests as a better argu-
ment for making such a decision [9-15]. For regions with
a high burden of TB and HIV, which urgently needed new
strategies for TB control, there are scarce data on cost-
effectiveness analysis of the PCR technique for TB diagno-
sis [11].
In the present study, in a hospital setting with a high bur-
den of TB and HIV, we investigated the cost-effectiveness
of a home-made colorimetric PCR (PCR dot-blot) to diag-
nose TB using expectorated sputum from patients sus-
pected of having PTB, in parallel with direct microscopy
by Ziehl-Neelsen staining for PTB diagnosis, using the
combination of positive culture with the clinical defini-
tion of PTB as the gold standard.
Methods
Setting and patient selection
Consecutive adults suspected of having PTB, referred to
the TB and HIV Reference Center, Parthenon Reference
Hospital (PRH) in Porto Alegre City, capital of Rio Grande
do Sul, State of Brazil, were studied prospectively, from
May 2003 to May 2004. Eligible patients were those: (1)
who reported more than 3 weeks of coughing; Patients
were excluded from the study if any of the following con-
ditions were met: (1) culture was contaminated; (2) when
expectorated sputum was not obtained (3) laboratory or
clinical data did not fulfill the PTB definition; (4) written
informed consent was not obtained from the study partic-
ipant. All clinical samples were sent to the Laboratory of
the State of RS, State Foundation for Research in Health,
Porto Alegre/RS/Brazil, (FEEPS/LACEN/RS) for laboratory
analysis. This study was approved by the Institutional
Review Boards of FEPPS/RS (n. 01/2002).
Suspects of PTB, after signing their written informed con-
sent, underwent a validated questionnaire with questions
regarding demographic variables and clinical history (e.g.:
smoking, alcohol abuse, HIV infection/AIDS)[16]. Chest
radiographs and physical examination were performed by
a respiratory specialist using a standardized form. Labora-
tory technicians and respiratory specialists were blinded
for the results of cultures and PCR dot-blot, and for the
chest radiographs results and clinical predictors, respec-
tively. HIV testing by ELISA (GenScreen HIV Plus® BioRad)
was performed, using Western blot (Genelabs® Diagnos-
tics) as a confirmatory test.
Case definition
PTB cases were defined as those with a positive culture for
MTB in the respiratory specimen or those with clinical and
radiological improvement after six months of solely anti-
TB treatment, as judged by three different chest physicians
in a blinded review, not involved in this study [17]. Not-
PTB was considered in patients whose acid-fast smear and
culture for MTB were negative and who had no chest radi-
ographic changes after six months of follow-up. PCR
results were not available for routine care or for the panel
of experts.
Gold standard criteria for PTB final diagnosis included all
PTB cases, confirmed or not by culture.
Routine laboratory process and performance evaluation
All sputum specimens were processed at the Public Refer-
ence Laboratory. All sputum specimens were tested by the
Ziehl-Neelsen method, cultured in Löwenstein Jensen and
identified according to Kubica's method [18].
The presence of the amplified fragment derived from the
IS6110 insertion element sequence in positive PCRs was
checked by electrophoresis with 2% agarose gel, stained
with ethidium bromide, and visualized under ultraviolet
light [10]. The positive and negative controls were
included in electrophoresis analysis.BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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The PCR colorimetric dot-blot assay was performed as
previously published [10]. Briefly, the biotinylated PCR
products were transferred to a nylon membrane and
hybridization was performed with a specific probe. The
detection of hybridization was performed using a conju-
gated streptavidin-alkaline phosphatase probe. The posi-
tive reaction was obtained by adding BCIP and NBT (5-
bromo-4-chloro-3-indoyl phosphate and nitro blue tetra-
zolium). The positive and negative controls were included
for each set of PCR. To detect specimen inhibitors in neg-
ative results, a tube of PCR mix for each specimen was
spiked with purified DNA target. All PCR tests with dis-
crepancies in results were tested in duplicate.
Costs
The cost components for each procedure included costs
incurred by the patient, laboratory costs, drugs, consuma-
bles and equipment costs. Number and level of staff
screening for TB in the hospital were considered as the
same in all strategies. Clinical, radiological and laboratory
staff costs were calculated from the salary base of Rio
Grande do Sul State of Brazil. For each procedure, costs
were attributed based on procedure costs of the Brazilian
Public Health System. For PCR, capital costs included the
cost of the thermocycler, reader and centrifuge. Running
costs (material costs used for each 1000 tests evaluated)
included all laboratory materials used in procedures. All
costs were expressed in US$, using an exchange rate of
US$ 1 = 3 R$ (REAIS), the average exchange rate from
2003 to 2004. In the treatment costs, costs were evaluated
related to the treatment of inpatients and outpatients. To
estimate the values that are spent by the public health sys-
tem of Brazil with the monitoring and control of TB in a
hospital and an outpatient unit, we simulated two differ-
ent scenarios: a) TB cases diagnosed in hospital wards
(inpatients), b) TB cases diagnosed in outpatient environ-
ment (outpatients).
The number of days considered to calculate the costs
related to the treatment of inpatients were considered as
the same days that were spent on each laboratory proce-
dure. It was hypothesized that the time to detect Mycobac-
terium tuberculosis in sputum culture from patients with
pulmonary tuberculosis may be a better indicator for the
duration of time of hospitalization[19]. The time to detect
M. tuberculosis in the culture was 30 days in this study. This
cohort is the same as previous published by our group
[20]. The median time to reveal growth of MTB was 30
days (interquartile range [IQR] 30 to 45) for smear/cul-
ture and the median time for detection of MTB by PCR
was 3.32 days (IQR 3.0 to 3.75), respectively (p < 0.01).
This value was used as the standard at which release from
isolation could be permitted [20]
The time spent on each laboratory procedure to provide
access to the result of the laboratory technique was
assumed to be 3 days for AFB smear plus in house PCR
(PCR dot blot), and 30 days for AFB smear plus culture.
The number of days considered to calculate costs was the
same as those spent on each laboratory procedure. The
number of days considered to calculate the cost of patient
travel costs was assumed to be 2 days for AFB smear plus
in house PCR (PCR dot blot), and 2 days for AFB smear
plus culture.
Total treatment included clinical officer and hospital
costs, assuming cost per pill, to be US$ 0.22, using 3 pills
per day, during 180 days; hospital room costs, US$ 4.16/
day; costs with salary of clinical staff and clinical consul-
tation, US$2.52 per patient and clinical nursing consulta-
tion, US$2.52 per patient.
Assuming that, during the treatment (6 months), in
ambulatory situation, 6 AFB smear test, 6 chest radio-
graphs, 6 consult of nurse and 2 consult of clinical were
performed, we used this parameters to estimated the costs
of ambulatory following the Brazilian recommendations
for treatment [21].
Assuming that, during the hospitalization (30 days), 4
AFB smear tests, 4 chest radiographs, 30 nurse and physi-
cian consultations were performed, we used these param-
eters to estimated the costs of inpatient assistance in
hospital, following the Brazilian recommendations for
treatment [21]. Staff salaries for the physician, nurse and
radiologist were considered to be US$6,400 per year, and
for the chest radiograph technician, the salary was
US$2,860 per year. The work days were considered 20
days for all staff.
The days of admission to the hospital were considered to
be the same number of days spent on each laboratory pro-
cedure. All estimated costs reflect an estimate of the public
health system of Brazil expenses with the monitoring and
control of TB.
The costs were expressed per 1000 suspects, according to
the specific bibliographic references for economic analy-
ses, thus, allowing the best decision for investment to be
made [22].
Cost effectiveness
A decision analytic model was developed using the Excel
7.0 software to estimate the costs of the routine diagnostic
procedures for diagnosis of PTB using sputum specimens:
1) AFB smear used with culture, and 2) AFB smear used
with PCR dot blot. We evaluated the the cost effectiveness
ratio of cost per case correctly diagnosed of TB, of cost per
case accurately diagnosed and treated, including treat-
ment of incorrectly diagnosed cases (e.g. false positive
patients), and of cost per case incorrectly diagnosed and
not treated (e.g. false negative patients). We assumed that,BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
Page 4 of 11
(page number not for citation purposes)
10 false negative patients may transmit M. tuberculosis to
100 individuals, and active TB is expected to occur in 5%
of those infected. In this study, the rate of TB in false neg-
ative patients was 13.3% for AFB smear plus Culture strat-
egy and 14.8% for AFB smear plus PCR dot-blot strategy.
Assuming the diagnosis of 1,000 TB cases, additional
active TB cases is expected to occur with AFB smear plus
culture and AFB smear plus PCR dot strategy in 66,5 and
74,0, respectively. We calculated the costs of missing false
negatives and compare the costs of each strategy [22].
A sensitivity analysis was performed to assess the effect of
the various parameters (TB prevalence, sensitivity, specifi-
city, and variable costs) on the conclusions.
Results
A total of 277 TB suspects, all with known HIV test results,
were enrolled. Prevalence of PTB was 46.2% (128/277)
overall and 54.0% (40/74) among HIV infected subjects.
Test performance and cost-effectiveness analyses were not
stratified by HIV status.
Test performance
Table 1 shows the yield and performance of each com-
bined procedure in detecting a PTB case. The positive
(LR+) and negative (LR-) likelihood ratios were 89 and
0.13 for AFB smear plus culture, and 5.31 and 0.18 for
AFB smear plus PCR-dot-blot, respectively. The inhibition
of two in house PCR was 1.9%. Twenty-three specimens
presented less than 50 CFU in culture, which is below the
detection limit of the PCR. These specimens were
included in the analysis.
Costs
Table 2A shows the costs at the health service level and
Table 2B shows costs due to laboratory investment. The
AFB smear plus PCR dot-blot require the lowest labora-
tory investment for equipment (US$ 20,000). Table 2C
shows costs incurred by patients. The AFB smear plus PCR
dot-blot require the lowest costs incurred by patients (US$
34.0 per patient).
Table 3 shows the total cost of screening 1000 suspects.
When total screening costs were considered, AFB smear
plus PCR dot blot costs were 3.8 times lower than AFB
smear plus Culture (US$ 1,498,660 versus US$
5,635,760).
When considering total cost (in US$) related to the treat-
ment (outpatients) per strategy, AFB smear plus PCR dot-
blot costs were 1.8 times lower than AFB smear plus Cul-
ture (US$ 849 versus US$ 1,589). When considering the
cost related to the treatment of inpatients, the total cost
for AFB smear plus PCR dot-blot was 5.5 times lower than
AFB smear plus Culture strategy (US$ 487 versus US$
2,686). When considering the cost related to the treat-
ment of outpatients and inpatients, the total cost for AFB
smear plus PCR dot-blot was 3.2 times lower than the AFB
smear plus Culture strategy (US$ 1,336 versus US$
4,275).
Table 4 shows the cost-effectiveness of screening 1000
PTB suspects, comparing AFB smear plus culture and AFB
smear plus PCR dot-blot. AFB smear plus PCR dot-blot
was less costly than AFB smear plus culture. When the
costs of treating all accurately diagnosed cases were con-
sidered, the cost-effectiveness was lower for AFB smear
plus PCR dot-blot (US$ 13,749) than the AFB smear plus
culture strategy (US$ 50,773). However, the cost of treat-
ment of false positives cases was less cost-effective for the
AFB smear plus PCR dot blot strategy than the AFB smear
plus culture strategy (US$ 18,674 versus US$ 1,589) for
Table 1: Sensitivities, specificities and likelihood ratios of AFB smear plus Culture and AFB smear plus PCR dot-Blot
Laboratory Results and Performance of methodsa Total number of suspects
N = 277
TB
N = 128
Not-TB
N = 149
Performance of AFB smear plus Culture Positive 111 1
Negative 17 148
SE SP LR+ LR-
87% 99% 89 0.13
Performance of AFB smear plus PCR dot-blot Positive 109 22
Negative 19 127
SE SP LR+ LR-
85% 85% 5.31 0.18
SE: Sensitivity, SP: Specificity, LR+: Positive Likelihood Ratio, LR-: Negative Likelihood Ratio. aThe performance of tests was calculated using specific 
formulae utilized by parallel tests: sensitivity (SE) of AFB smear with culture: (SEzn + SEculture) - (SEzn × SEculture), specificity (SP) of AFB smear with 
culture: SPzn.X SPculture, predictive values (PV) and likelihood ratio (LR), according to literature [32].BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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outpatients. The cost of treatment of false positives cases
was less cost-effective for the AFB smear plus PCR dot blot
strategy than the AFB smear plus culture strategy (US$
10,715 versus US$ 2,686) for inpatients. The cost of treat-
ment of false negatives cases was more cost-effective for
the AFB smear plus PCR dot blot strategy than the AFB
smear plus culture strategy (US$ 25,382 versus US$
72,675).
Considering the aim of this study was to compare the
costs of AFB smear plus culture and AFB smear plus PCR
dot blot strategies, Table 5 presents a sensitivity analysis to
compare the cost-effectiveness ratio of the two strategies,
adjusting for different features. The ratio of cost-effective-
ness was 3.7 in most adjustments. Considering the high
prevalence of TB (60%), the AFB smear plus PCR dot-blot
was more cost effective than the current situation (preva-
lence, 46%). Considering low prevalence of TB (10%), the
PCR dot-blot was less cost effective than the status quo, but
the costs decreased with the increase in TB prevalence. If
the running costs of PCR dot-blot were reduced by 22%,
the AFB smear plus PCR dot blot was more cost effective
than the AFB smear plus culture strategy.
Discussion
The strategy of comparing rapid techniques, such as PCR,
to standard techniques, such as AFB smear/culture could
improve the quality of diagnosis and reduce delayed iden-
Table 2: Costs in US$ of TB diagnosis in Brazil
A. Health service costs
Staff Number Salaries of all staff per 
year
(US$)
Staff Cost per day
(US$)
Time spent until access to 
result
(days)
AFB smear plus Culture 2 9,260 39 30
AFB smear plus PCR-dot-
blot
29 , 2 6 0 3 9 3
B. Laboratory costs
Equipment
(US$)
Annualization Years Running costs per 1000 
suspects
(US$)
Running costs per 
examination
(US$)
AFB smear plus Culturea 22,667 5 12,333 12.33
AFB smear plus PCR-dot-
blotb
20,000 5 12,833 12.83
C. Estimated costs incurred by patients, including costs for travel, food and income lossd
AFB smear plus Culture (US$)
(outpatients and inpatients)
AFB smear plus PCR dot-blot 
(US$) (inpatients and outpatients)
Travel 1,000 1,000
Food 3,000 3,000
Income Lossc 186,800 30,000
Total patients Cost 190,800 34,000
a Microscopic and Laminar Flow Cabinets,;
bThermocycler reader, Centrifuge and Laminar Flow Cabinets. Other equipments were not included,
c Income loss of patients was calculated from monthly salary base of Brazil (US$117) and was based on proportional days spent by patients until 
access to the result of each laboratory procedure. Patient costs were estimated using the average of two visits to the laboratory for the PCR 
procedure and for AFB smear and culture procedures for outpatients; Travel cost was considered as US$ 0.8 (one way by bus). Food was 
considered as US$3.3 per meal. Base salary in Brazil was considered (US$5. 83 per day/20 days of the work). For inpatients was considered just 
income loss; Staff costs in the laboratory were based on proportional days spent on each laboratory procedure;Costs of consumables and 
equipment were provided by the program as well as by the manufacturer. We annualized the capital cost of the equipment for 5 years, according to 
the literature [25]. PCR capital costs included the cost of the thermocycler, reader and centrifuge. Building costs were not included. Opportunity 
costs were not applicable.BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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Table 3: Costs (in US$) of screening 1000 TB suspects, comparing AFB smear plus Culture and AFB smear plus PCR dot-blot
AFB smear plus Culture AFB smear plus PCR dot-blot
Total cases TB 128 128
3. A Health Service costs
Labor costsa
Laboratory Costs 3,283 13,067
Investment costs 123 194
Running costs 12,333 12,833
Treatment costs
Treatment costs (ambulatory/outpatients) 1,589 849
Treatment costs (hospitalization/inpatients) 2,686 487
Treatment costs (outpatients and inpatients) 4,275 1,336
Diagnostic Service costs per daya
Cost staff per time spent in each laboratory procedure 1,158 116
3. B1. Patient cost (ambulatory/outpatients)d
Travel 11
Food 33
Income Loss 12 12
3. B2. Patient cost (hospital/inpatients)d
Travel 00
Food 00
Income Loss 174.8 18
3. C Total costs for 1000 TB suspects
Total Patient costs 190,800 34,000
Total Health Service costs 5,444,960 1,464,660
Total Screening costs 5,635,760 1,498,660
a For each procedure, costs were attributed based on procedure costs of the Brazilian Public Health System (US$ 1.4 for AFB smear and US$ 1.9 
for Culture) and from CDCT/FEPPS (US$ 11.7 for PCR dot-blot), assuming investment laboratory equipment for 5 years; bStaff salary was 
considered; for laboratory technician, US$2,860 per year; for Laboratory technologist, US$6,400 per year. Staff costs in the laboratory were based 
on proportional days spent on each laboratory procedure; Staff salary was considered for clinical physician, nurse and radiologist; US$6,400 per 
year; for the X-RAY technician, salary was US$2,860 per year. cThe days of hospitalization were considered as the same as the days spent on each 
laboratory procedure. The time spent on each laboratory procedure until access to the result of the laboratory technique was assumed to be 3 
days for AFB smear plus in house PCR (PCR dot blot), and 30 days for AFB smear plus Culture. Total treatment included clinical officer and hospital 
costs, assuming US$ 0.22 cost per pill, using 3 pills for day, during 180 days; hospital room costs, US$ 4.16/day; costs of salary of staff clinical; clinical 
consultation cost, US$2.52 per patient; clinical nursing consultation, US$2.52 per patient. Assuming that during the treatment of inpatients (4 
months) 4 AFB smear and 4 chest radiograph were performed, and during the treatment of outpatients (6 months) 6 AFB smear and 6 chest 
radiograph were performed, following the Brazilian recommendations for treatment [21];
d Travel for AFB smear strategies was considered as 2 days for AFB smear plus Culture strategy; and 2 days for AFB smear plus PCR dot-blot. Food 
and income loss for AFB smear strategies was considered as 30 days for AFB smear plus Culture strategy; and 3 days for AFB smear plus PCR dot-
blot The health service costs analysis was based on processing 50 AFB smear slides, 86 samples for each in house PCR and 14 cultures per day. AFB 
smear plus Culture and in house PCR were performed by two trained staff, respectively. Costs of chest physicians were considered the same for all 
strategies. Running costs were calculated from investments required to examine 1000 smears.BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
Page 7 of 11
(page number not for citation purposes)
tification of mycobacterial infections. This is especially
crucial among hospitalized PTB suspects, in which the
atypical clinical presentation and mortality rate are more
frequent, and where it is sometimes difficult to obtain
multiple respiratory specimens [11,23]. Additionally, AFB
smear alone cannot distinguish TB from mycobacteria
other than TB [24]. In this study, in a setting with a high
prevalence of TB/HIV (54.0%), we evaluated sensitivity,
specificity, likelihood ratios, predictive values and com-
pared the cost-effectiveness of the strategies; AFB smear
plus culture and AFB smear plus PCR dot-blot for diagno-
sis of PTB [25].
Although the AFB smear plus culture strategy presented
the highest performance for PTB diagnosis, AFB smear
plus PCR dot blot strategy had a similar sensitivity (85%)
and a similar negative low likelihood ratio (0.18) to those
of AFB smear plus culture (87%, 0.13), respectively, sug-
gesting that this strategy may offer improvement for ruling
out TB diagnosis for pulmonary TB suspects, including
HIV infected individuals, where it is critical to initiate
prompt, specific treatment and a delayed diagnosis can be
lethal. Additionally, this strategy could reduce the risk of
dissemination and spread to other hospitalized patients
and health care personnel [2,26].
The specificity of AFB smear plus PCR dot-blot (85%) was
similar to a series described (84% to 87%) in developing
countries, also using automated nucleic acid amplifica-
tion tests (NAA), and lower than that described (>95%) in
industrialized countries [6,23,27,28]
The low sensitivities found in AFB smear plus PCR dot-
blot (85%) may be due to the presence of inhibitors that
remain in the specimen after the extraction procedure, or
a small number of mycobacteria that are unequally dis-
tributed in the test suspension or that exist below the
detection limit of both in house PCR tests (PCR dot blot)
(50 CFU)[10]. With regard to false negative results, 57.9%
(11/19) for PCR dot-blot was below the detection limit of
the amplification test. The proportion of inhibitors was
1.9% for the in house PCR, similar to those used in NAA
tests (0.85% to 22.7%) [12,28]. The low copy numbers of
IS6110 (insertion element) in MTB, are reported to be a
factor in decreased sensitivity, although this has not been
reported in Brazil[20].
To make rational decisions about the implementation of
NAA in the medical routine, cost-effectiveness studies are
essential [29-31]. Such studies provide insight into the
composition of different cost components, which may be
the most important factor from the patient and the health
service's perspectives [32]. Here, we compared the cost-
effectiveness of AFB smear with in house PCR and with cul-
ture on the first sputum specimen collection, including
staff costs, using culture and clinical evaluation as the gold
standard, in contrast to the cost-effectiveness analysis
described by van Cleef et al in a reference ambulatory
clinic in Kenya, where only culture for mycobacteria was
used as the gold standard [11,33].
In this study, we used the criteria that a strategy for ruling
out of TB diagnosis is cost-effective when it is less costly
and when it is at least as effective as the AFB smear plus
culture strategy. We found that the use of AFB smear plus
PCR dot-blot was less cost-effective per case correctly diag-
nosed, than the cost-effectiveness described using the
decision model for automated PCR (Roche Mycobacte-
rium Tuberculosis Amplicor PCR system), probably due
to the lower accuracy observed with in house PCR tech-
niques [11,33]. The cost-effectiveness of AFB smear plus
PCR dot-blot depends strongly on sensitivity and specifi-
city of tests. Others factors are important, such as the costs
of the health service and also patient costs, the later usu-
ally not included in the analysis carried out in developing
nations. In this study, we included these factors in the
cost-effectiveness analysis, which may possibly be the
cause for the difference found in relation to the current lit-
erature. The costs of hospital TB screening may be overes-
timate. For the hospitalization costs we used the same
days spent to detect M. tuberculosis in culture (30 days) as
proposed by others [19]. The median the days of hospital-
ization of smear negative pulmonary TB suspects fre-
quently vary from 15 to 25 days in other sites in Brazil, but
in this study, it was not measured. The cost-effectiveness
per case correctly diagnosed for the AFB smear plus PCR
dot-blot strategy was more cost effective than the AFB
smear plus culture strategy (ratio of 3.7). The costs for
every correctly-diagnosed TB patient were, thus, 3.7 times
lower for the AFB smear plus PCR dot-blot than for the
AFB smear plus culture, in contrast to previous reports for
automated PCR (ratio of 1.8), where this technique was
compared to PCR with the smear microscopy routine
[11]. The cost-effectiveness per case accurately diagnosed
and treated, including treatment of falsely diagnosed cases
in AFB smear plus PCR dot-blot, was more cost-effective
than for the AFB smear plus culture strategy (ratio of 3.7).
The costs for every case accurately diagnosed and treated,
including treatment of falsely diagnosed TB patient were
thus 3.6 times lower for AFB smear plus PCR dot-blot than
for AFB smear plus culture. Furthermore, the cost-effec-
tiveness per case incorrectly diagnosed and not treated,
was more cost-effective for AFB smear plus PCR dot-blot
than for the AFB smear plus culture strategy (ratio of 3.4).
The costs for every case incorrectly diagnosed and not
treated TB patient were thus 3.4 times lower for AFB smear
plus PCR dot-blot than for AFB smear plus culture.
The over diagnosis due to the low specificity of the in house
PCR might indeed be a barrier in the decision to invest inBMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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Table 4: Costs (in US$) and Cost-effectiveness (in US$) of screening 1000 TB suspects, comparing AFB smear plus Culture and AFB 
smear plus PCR dot-blot.
AFB smear plus Culture AFB smear plus PCR dot-blot
Total number of accurately diagnosed cases of TB 111 109
Total number correctly diagnosed cases of non TB 148 127
False positives 12 2
False negatives 17 19
Estimate of false negatives in 1000 TB suspects 133 (13.3%) 148 (14.8%)
Estimate of cases of TB (5%) using the estimative of transmission of 
false negatives in 1000 TB suspects
66,5 74
4. A Total Costs (US$) (US$)
Total Health Service Costs 5,444,960 1,464,660
Total Patient Costs 190,800 34,000
Total Screening Costs 5,635,760 1,498,660
Total Screening Costs per patient 5,635 1,498
4. B Cost-effectiveness of screening of 1000 suspects
Cost per accurately diagnosed case of TB 50,773 13,749
Cost per accurately diagnosed case of TB, considering only health 
service costs
49,053 13,437
Cost per accurately diagnosed case of TB, considering only patient 
cost
1,720 312
Cost of treating all correctly diagnosed TB cases (true positives cases) 
(ambulatory/outpatients)
176,338 92,523
Cost of treating all correctly diagnosed TB cases (true positives cases)
(hospital/inpatients)
298,187 53,087
Cost of treating all falsely diagnosed TB cases (false positives cases) 
(ambulatory/outpatients)
1,589 18,674
Cost of treating all falsely diagnosed TB cases (false positives cases) 
(hospital/inpatients)
2,686 10,715
Cost per case of TB correctly diagnosed and case of TB falsely diag-
nosed and treated (true positives and false positives)a
50,319 11,440
Cost of treatment of false negatives cases of TB 
(Treatment costs vs false negative cases)
72,675 25,382
Cost per case of non-TB correctly and incorrectly diagnosed and not 
treated
(true negatives and false negatives)
34,156 10,260
Cost of return of all false negatives to the health service (Estimate of 
cases of TB (5%) using the estimative of transmission of false nega-
tives in 1000 TB suspects vs Total Screening Costsb
374,778,045 110,900,055
a including treatment of falsely diagnosed cases, b assuming that one false negative transmits TB to 10 individuals and these 5% have TB and the cost-
effectiveness was expressed for 1000 suspects [35]BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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these tests. However, in our study, AFB smear plus PCR
dot-blot (PCR in house) was more cost-effective than AFB
smear plus culture, confirming the potential use of in
house PCR techniques in the diagnostic routine for ruling
out of TB diagnosis [12,29-31]. Another reason for the use
of the in house PCR is that AFB smear plus culture is time
consuming and labor intensive. Additionally, the PCR
method is patient friendly, reducing costs to patients and,
most importantly, PCR is not influenced by the HIV status
of the patient [23]
Middle-income countries, like Brazil, have to consider the
economic burden of managing false-negative results. The
cost of return of all false negative patients to the health
services was higher for AFB smear plus culture than for
AFB smear plus PCR dot-blot. Some studies have reported
the importance of considering the costs of false-negative
patients [11,33]. When these costs were associated with
total screening costs, the costs for every incorrectly diag-
nosed and not-treated case were higher in AFB smear plus
culture than for the AFB smear plus PCR dot-blot strategy.
The sensitivity analysis, comparing the cost-effectiveness
of AFB smear plus culture and AFB smear plus PCR dot-
blot, and adjusting different scenarios for TB prevalence,
shows that the ratio of cost-effectiveness remains more or
less the same in most adjustments. Some gains in cost-
effectiveness can be obtained when the sensitivity and
specificity of PCR are adjusted to 95%, according to results
reported previously that state that a sensitivity of higher
than 80% can be a factor in increasing the cost-effective-
ness of PCR methods [33].
When reducing the cost of the PCR dot-blot to US$ 10 per
test, the cost-effectiveness of the AFB smear plus PCR dot-
blot strategy also decrease; such an effect has also been
described by others for different methods when the cost of
PCR is reduced [11,23,24,33]. It is also expected that cost
can be reduced with time and increased utilization [34]. In
house PCR tests are estimated to cost about US$ 5-10. A
price reduction to US$ 6 would adjust the cost effective-
ness of PCR to the same level of smear microscopy [33].
The cost-effectiveness of the AFB smear plus PCR dot-blot
strategy described in this study was similar to other strate-
Table 5: Sensitivity analysis (in US$) based on screening of 1000 suspects, comparing AFB smear plus Culture, and AFB smear plus 
PCR dot-blot
Cost per accurately 
diagnosed 
case of TB
Cost per case accurately 
diagnosed 
and treated, including 
treatment of  
falsely diagnosed cases
Cost per case incorrectly 
diagnosed  
and not treated**
Component Current  
situation
Adjustment AFB 
smear 
plus 
Culture
AFB  
smear 
plus  
PCR  
dot-blot
Ratio AFB 
smear  
plus 
Culture
AFB  
smear  
plus  
PCR  
dot-blot
Ratio AFB 
smear  
plus 
Culture
AFB 
smear  
plus PCR 
dot-blot
Ratio
TB 
prevalence
46% No 
adjustment
50,773 13,749 3.7 55,501 15,190 3.6 22,045,767, 5,836,887 3.8
10% 233,554 63,246 3.7 255,304 69,874 3.6 124,926,015 27,725,214 4.5
20% 116,777 31,623 3.7 127,652 34,937 3.6 20,821,002
$
3,960,745 5.3
40% 58,389 15,812 3.7 63,826 17,469 3.6 9,609,693 1,980,372 4.9
60% 38,926 10,541 3.7 42,551 11,646 3.6 505,773 94,303 5.4
Sensitivity  
PCR 
dot-blot
85% 95% 46,577 12,386 3.7 50,914 13,683 3.7 3,097,339 916,536 3.4
Specificity  
PCR 
dot-blot
85% 95% 39,688 10,554 3.7 43,384 11,659 3.7 2,639,282 780,992 3.4
PCR 
dot-blot  
running 
costs*
12,833 10,000 50,772 13,723 3.7 55,501 15,164 3.7 20,045,767 5,825,852 3.8
* assuming that PCR dot-blot running costs could be decreased by 22%, ** assuming that one false negative transmits TB to 10 individuals and these 
5% have TB and the cost-effectiveness was expressed for 1000 suspects.BMC Infectious Diseases 2009, 9:216 http://www.biomedcentral.com/1471-2334/9/216
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gies, when lower TB prevalence made PCR more expensive
for diagnosis of PTB [11,33].
Limitations
a. Since the respiratory specialists were blinded to culture
PCR results and laboratory technicians blinded to chest
radiograph and clinical predictor results, the study does
not mimic the use of PCR dot-blot under field conditions,
and, as such, the cost-effectiveness is estimated, not meas-
ured.
b. In-house PCR results used in this study are not necessar-
ily generalizable to other situations, as in house PCR are
not standardized and is usually associated with low repro-
ducibility, unless the replicating sites use the exact same
in-house PCR [5]. Therefore, results obtained by in house
PCR techniques should be used only by local health serv-
ice only if the laboratory follows strictly good laboratory
practices established by the international guidelines and is
certified by regulatory agencies.
c. Twenty-three specimens presented less than 50 CFU in
culture were included in the analysis, which is below the
detection limit of the PCR test. Partial loss of mycobacte-
rial homogeneity, leading to unequal distribution in the
test suspension, may be due to the division of the suspen-
sion into three aliquots for use in laboratory tests. Addi-
tionally, excluding those samples would increase the in
house PCR sensitivity, but it would not represent the rou-
tine conditions
d. Stratification of different diagnostic strategy results by
HIV status was not performed.
e. Mortality was not measured for either strategy.
f. In the treatment costs analysis, were not included the
cost related to: a) the inadequate use of non anti-TB drugs;
b) the adverse effects of the inadequate use of anti-TB
drugs for non-TB subjects, c) the occurrence of drug-resist-
ant TB, d) the impairment to delay of treatment and of
other physical conditions caused by adverse effects of
drugs.
g. Isolation use or contact investigation was not included
in the analysis
Conclusions
This study suggests that novel molecular diagnostic tests
have the potential to be cost-effective tools in the fight
against TB. Our study showed that the use of AFB smear
plus PCR dot-blot to diagnose TB, employing the respira-
tory specimen can be a cost-effective alternative, especially
in hospitals of developing nations with a high prevalence
of TB and HIV. AFB smear plus PCR dot-blot strategy
showed a great improvement in sensitivity, negative pre-
dictive value, and offered an improvement for ruling out
of pulmonary TB diagnosis. However, inter laboratory
and cost-effectiveness studies in other settings are
required to evaluate the performance of the PCR dot-blot
under field conditions before it may be introduced for
routine use.
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